Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3 CNS 3 Other hematologic neoplasm 2 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Genitourinary 1 Gastrointestinal 1 Breast 1

Conditions

All Solid Tumors 1

Interventions

pembrolizumab 41 Injections 39 toripalimab 23 Nivolumab 22 Cisplatin 19 Pemetrexed 18 Carboplatin 18 Cyclophosphamide 17 Paclitaxel 14 Bevacizumab 14 fludarabine 12 Gemcitabine 11 tislelizumab 10 Ipilimumab 10 spartalizumab 9 Irinotecan 9 atezolizumab 8 Docetaxel 8 Oxaliplatin 7 Leucovorin 7 Fluorouracil 7 Capecitabine 6 sintilimab 5 Interleukin-2 5 Albumin-Bound Paclitaxel 5 130-nm albumin-bound paclitaxel 5 trifluridine tipiracil drug combination 4 sotorasib 4 pazopanib 4 palbociclib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Pharmaceutical Preparations × Other solid neoplasm × Clear all

NCT01711398 2015-02-12

IP N02

Elro Pharma

Phase 1/2 Completed

Other solid neoplasm

All Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡